<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894591</url>
  </required_header>
  <id_info>
    <org_study_id>JZP712-402</org_study_id>
    <nct_id>NCT04894591</nct_id>
  </id_info>
  <brief_title>To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)</brief_title>
  <acronym>SCLC</acronym>
  <official_title>EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage&#xD;
      small cell lung cancer (SCLC) in real-world clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase IV, prospective, single arm, multi-center, observational study to collect safety and&#xD;
      outcome data of Zepzelca in adult participants with extensive stage SCLC previously exposed&#xD;
      to at least one line of treatment with platinum-based chemotherapy. Patients enrolled in the&#xD;
      study will be encouraged to complete patient reported outcome (PRO) questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Treatment Patterns in Participants Measured by Number of Days in a Cycle, Dose Intensity, Number of Dose Reductions and Dose Delays, Number of Cycles Summarized by Number of Previous Lines of Therapy</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing Safety and Tolerability of Zepzelca by Assessing the Number of Participants with Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response to Zepzelca</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Health-related Quality of Life (HRQOL) using Patient Reported Outcome (PRO) Questionnaires</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Other Subgroups of Interest</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) in Other Subgroups of Interest</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) in Other Subgroups of Interest</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) in Other Subgroups of Interest</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing Safety and Tolerability of Zepzelca by Assessing the Number of Participants with SAEs and AESI in Subgroups of Interest</measure>
    <time_frame>up to 24 months after first infusion</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Extensive-stage Small-cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zepzelca</intervention_name>
    <description>Zepzelca is administered by intravenous infusion over 60 minutes every 21 days. Date, dose prescribed and received will be collected at each Zepzelca infusion.</description>
    <other_name>lurbinectedin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants with extensive SCLC treated with Zepzelca.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has initiated or will be receiving Zepzelca treatment in line with the&#xD;
             Zepzelca US prescribing information.&#xD;
&#xD;
          -  Decision to initiate treatment with Zepzelca was made as per investigator's routine&#xD;
             treatment practice prior to enrollment in the study.&#xD;
&#xD;
          -  Patient, or a legally acceptable representative, signed the informed consent before&#xD;
             any study-related activities are undertaken.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who discontinued a prior Zepzelca treatment due to adverse events.&#xD;
&#xD;
          -  Patient who received more than 2 cycles of Zepzelca treatment in their current&#xD;
             treatment schedule.&#xD;
&#xD;
          -  Patient received treatment with any investigational agent within 30 days prior to&#xD;
             first Zepzelca infusion or plans to use another investigational agent while receiving&#xD;
             Zepzelca.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Navit Naveh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Jazz Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raj Hanvesakul, MBChB PhD</last_name>
    <role>Study Director</role>
    <affiliation>Jazz Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Navit Naveh, MD</last_name>
    <phone>+1 917-828-2921</phone>
    <email>Navit.Naveh@jazzpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raj Hanvesakul, MBChB PhD</last_name>
    <phone>+44 1865 399753</phone>
    <email>raj.hanvesakul@jazzpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology And Oncology</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid-Illinois Hematology &amp; Oncology Associates, Ltd.</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

